Efficacy and Safety of 177Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and Safety of 177Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study

Published:2020-08 Issue:2 Volume:78 Page:148-154
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Gafita Andrei,Fendler Wolfgang P.,Hui Wang,Sandhu Shahneen,Weber Manuel,Esfandiari Rouzbeh,Calais Jeremie,Rauscher Isabel,Rathke Hendrik,Tauber Robert^ORCID,Delpassand Ebrahim S.,Weber Wolfgang A.,Herrmann Ken,Czernin Johannes,Eiber Matthias,Hofman Michael S.

Funder

Prostate Cancer Foundation of Australia

Endocyte

Australian Nuclear Science and Technology Organisation

Movember Australia

Prostate Cancer Foundation

VCA

Deutsche Forschungsgemeinschaft

Peter MacCallum Foundation

Publisher

Elsevier BV

Subject

Urology

Reference13 articles.

1. Mechanisms of bone metastasis;Roodman;N Engl J Med,2004

2. Bone metastases: an overview;Macedo;Oncol Rev,2017

3. Third-line treatment and (177)Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review;von Eyben;Eur J Nucl Med Mol Imaging,2018

4. Violet J, Sandhu S, Iravani A, et al. Long term follow-up and outcomes of re-treatment in an expanded 50 patient single-center phase II prospective trial of Lutetium-177 ((177)Lu) PSMA-617 theranostics in metastatic castrate-resistant prostate cancer. J Nucl Med. In press. https://doi.org/10.2967/jnumed.119.236414.

5. TheraP: a randomized phase 2 trial of (177) Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603);Hofman;BJU Int,2019

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trends in cancer imaging;Trends in Cancer;2024-09

2. A Practical Guide to the Pearls and Pitfalls of PSMA PET Imaging;Seminars in Nuclear Medicine;2024-01

3. Theranostics - a sure cure for cancer after 100 years?;Theranostics;2024

4. Advances in prostate cancer treatment: Radionuclide therapy for prostate cancer;Advances in Cancer Research;2024

5. Sequential and Combination Therapies of²²³RaCl₂and Prostate-Specific Membrane Antigen Radioligand Therapy;Journal of Nuclear Medicine;2023-10-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3